.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Fuji
Chinese Patent Office
McKesson
Healthtrust
Argus Health
Harvard Business School
QuintilesIMS
Julphar
Baxter

Generated: September 22, 2017

DrugPatentWatch Database Preview

SYMBYAX Drug Profile

« Back to Dashboard

What is the patent landscape for Symbyax, and when can generic versions of Symbyax launch?

Symbyax is a drug marketed by Lilly and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has forty-seven patent family members in twenty-five countries.

The generic ingredient in SYMBYAX is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.

Summary for Tradename: SYMBYAX

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list92
Clinical Trials: see list3
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SYMBYAX at DailyMed

Pharmacology for Tradename: SYMBYAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-001Apr 9, 2007ABRXYesNo► Subscribe► Subscribe ► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-005Dec 24, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-002Dec 24, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-002Dec 24, 2003ABRXYesNo► Subscribe► SubscribeYYY ► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-003Dec 24, 2003ABRXYesYes► Subscribe► SubscribeYYY ► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-004Dec 24, 2003ABRXYesNo► Subscribe► SubscribeYYY ► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-005Dec 24, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-005Dec 24, 2003ABRXYesNo► Subscribe► SubscribeYYY ► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-003Dec 24, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-001Apr 9, 2007ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SYMBYAX

Paragraph IV activity for: SYMBYAX

Drugname Dosage Strength RLD Submissiondate
olanzapine and fluoxetine hydrochlorideCapsules3 mg/25 mgSymbyax5/8/2008
olanzapine and fluoxetine hydrochlorideCapsules6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mgSymbyax1/10/2005

Premature patent expiration for: SYMBYAX

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
SYMBYAX
► Subscribe

International Patent Family for Tradename: SYMBYAX

Country Document Number Estimated Expiration
Slovakia17512000► Subscribe
Australia761510► Subscribe
China1219877► Subscribe
Czech Republic20004279► Subscribe
Eurasian Patent Organization200001218► Subscribe
World Intellectual Property Organization (WIPO)9735586► Subscribe
Brazil9911049► Subscribe
Japan2000507945► Subscribe
Australia2543097► Subscribe
World Intellectual Property Organization (WIPO)9961027► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Mallinckrodt
Federal Trade Commission
US Department of Justice
Farmers Insurance
Dow
US Army
Covington
Queensland Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot